SEC Tracker
Get the app

LENSAR LNSR

LENSAR FY 2022: revenue $35.4M, up 3%; diluted EPS −$1.96

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers LENSAR reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$35.4M+3% from $34.5M in FY 202110-K income statement, on EDGAR
  2. Net income−$19.9MAgainst −$19.6M in FY 202110-K income statement, on EDGAR
  3. Diluted EPS−$1.96Against −$2.09 in FY 202110-K income statement, on EDGAR
  4. Cash and cash equivalents$14.7M−54% from $31.6M in FY 202110-K balance sheet, on EDGAR
  5. Cash from operations−$14.9MAgainst −$9.0M in FY 202110-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when LENSAR files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. CVRx CVRX public float $112M, Jun 30, 2025
  2. TriSalus Life Sciences TLSI public float $112M, Jun 30, 2025
  3. Shoulder Innovations SI
  4. KORU Medical Systems KRMD public float $119M, Jun 30, 2025
  5. Mobia Medical MOBI

Data on this page was fetched . The filing on SEC.gov is the record.